AssetMark’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
AssetMark's HQL Position: Q3 2026 in Review
AssetMark reduced its abrdn Life Sciences Investors (HQL) stake by 30% in Q3 2026, selling an estimated $2.24K and leaving 265 shares worth $4.96K. The position accounts for ﹤0.01% of the portfolio, ranked #2775.
AssetMark first reported a position in HQL in Q2 2025 and has held it in 6 quarters since. The position peaked at $7.52K in Q2 2026. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2026.
- AssetMark held 265 shares of abrdn Life Sciences Investors worth $4.96K as of Q3 2026.
- AssetMark sold 111 abrdn Life Sciences Investors shares in Q3 2026, an estimated $2.24K.
- abrdn Life Sciences Investors made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2775 holding.
- AssetMark first reported a position in abrdn Life Sciences Investors in Q2 2025 and has held it in 6 quarters since.
- AssetMark's abrdn Life Sciences Investors position peaked at $7.52K in Q2 2026.
- 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.